New pill combo aims to ease stubborn shingles nerve pain
NCT ID NCT07275762
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a new tablet called Y-4, which combines two drugs (pregabalin and riluzole), can better relieve postherpetic neuralgia—persistent nerve pain after shingles—compared to pregabalin alone. About 160 adults in China will take either Y-4 or pregabalin for 14 weeks. Researchers will track pain scores and side effects to see if the combination is more effective and safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Y-4 (a combination of pregabalin and riluzole)
What this could lead to
If it works, Y-4 could offer better pain relief for people with lingering nerve pain after shingles.
What could go wrong
This is an early Phase 2 trial with only 160 participants, so results may not apply to everyone. The added riluzole may cause side effects without improving pain control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTHERPETIC NEURALGIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital for Skin Diseases, Chinese Academy of Medical Sciences
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••